CR20220110A - Profármacos antivirales y composiciones farmacéuticas de los mismos - Google Patents

Profármacos antivirales y composiciones farmacéuticas de los mismos

Info

Publication number
CR20220110A
CR20220110A CR20220110A CR20220110A CR20220110A CR 20220110 A CR20220110 A CR 20220110A CR 20220110 A CR20220110 A CR 20220110A CR 20220110 A CR20220110 A CR 20220110A CR 20220110 A CR20220110 A CR 20220110A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
antiviral prodrugs
prodrugs
antiviral
hiv
Prior art date
Application number
CR20220110A
Other languages
English (en)
Inventor
Arnab Kumar Chatterjee
Anil Kumar Gupta
Anders Mikal Eliasen
Sean Barry Joseph
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of CR20220110A publication Critical patent/CR20220110A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

Diésteres de 4'-etinil-2-fluoro-2'-desoxiadenosina y suspensiones parenterales acuosas de los mismos proporcionan una supresión viral in vivo extendida del virus de inmunodeficiencia humana (VIH).
CR20220110A 2019-09-11 2020-09-11 Profármacos antivirales y composiciones farmacéuticas de los mismos CR20220110A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962898679P 2019-09-11 2019-09-11
PCT/US2020/050511 WO2021050956A1 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
CR20220110A true CR20220110A (es) 2022-06-16

Family

ID=74866690

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20220109A CR20220109A (es) 2019-09-11 2020-09-11 Profármacos antivirales y formulaciones de los mismos
CR20220110A CR20220110A (es) 2019-09-11 2020-09-11 Profármacos antivirales y composiciones farmacéuticas de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20220109A CR20220109A (es) 2019-09-11 2020-09-11 Profármacos antivirales y formulaciones de los mismos

Country Status (15)

Country Link
US (3) US20220332751A1 (es)
EP (2) EP4028020A4 (es)
JP (2) JP2022547558A (es)
KR (2) KR20220066302A (es)
CN (3) CN114793421B (es)
AU (2) AU2020346908A1 (es)
BR (2) BR112022004424A2 (es)
CA (2) CA3150467A1 (es)
CL (2) CL2022000587A1 (es)
CO (2) CO2022005128A2 (es)
CR (2) CR20220109A (es)
IL (2) IL290861A (es)
MX (2) MX2022002897A (es)
PE (2) PE20221037A1 (es)
WO (2) WO2021050956A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117982682A (zh) 2017-07-11 2024-05-07 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
WO2021116872A1 (en) * 2019-12-09 2021-06-17 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
AR121620A1 (es) * 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
US11975012B2 (en) 2020-05-29 2024-05-07 Gilead Sciences, Inc. Remdesivir treatment methods
AU2021296841A1 (en) 2020-06-24 2023-02-16 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
PT4204421T (pt) 2020-08-27 2024-06-25 Gilead Sciences Inc Compostos e métodos para o tratamento de infeções virais
EP4320128A1 (en) 2022-03-02 2024-02-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694693B1 (fr) * 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090274686A1 (en) * 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
WO2013090420A2 (en) * 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2017053216A2 (en) * 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
EP3386512B1 (en) * 2015-12-10 2023-11-22 Merck Sharp & Dohme LLC Antiviral phosphodiamide prodrugs of tenofovir
KR102626210B1 (ko) * 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
EP3762396A1 (en) * 2018-03-07 2021-01-13 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
TW202118496A (zh) * 2019-07-27 2021-05-16 美商布里生物科學股份有限公司 腺苷衍生物及包含其之醫藥組合物

Also Published As

Publication number Publication date
AU2020346908A2 (en) 2022-06-16
CO2022004681A2 (es) 2022-07-19
MX2022002899A (es) 2022-05-16
US20230390318A1 (en) 2023-12-07
AU2020346908A1 (en) 2022-03-24
BR112022004424A2 (pt) 2022-05-31
US20220332751A1 (en) 2022-10-20
EP4028019A1 (en) 2022-07-20
WO2021050961A1 (en) 2021-03-18
KR20220066303A (ko) 2022-05-24
JP2022547978A (ja) 2022-11-16
AU2020346907A2 (en) 2022-06-16
CN114929236A (zh) 2022-08-19
CO2022005128A2 (es) 2022-05-10
BR112022004417A2 (pt) 2022-06-21
WO2021050956A1 (en) 2021-03-18
EP4028020A4 (en) 2023-09-27
IL290861A (en) 2022-04-01
US20220323476A1 (en) 2022-10-13
CL2022000601A1 (es) 2022-10-28
CA3150418A1 (en) 2021-03-18
CN114793421A (zh) 2022-07-26
IL290919A (en) 2022-04-01
EP4028019A4 (en) 2024-04-17
CR20220109A (es) 2022-06-07
PE20221036A1 (es) 2022-06-17
PE20221037A1 (es) 2022-06-17
MX2022002897A (es) 2022-05-16
CA3150467A1 (en) 2021-03-18
JP2022547558A (ja) 2022-11-14
CN114929236B (zh) 2024-06-07
CL2022000587A1 (es) 2022-10-28
CN118580291A (zh) 2024-09-03
KR20220066302A (ko) 2022-05-24
CN114793421B (zh) 2024-09-13
AU2020346907A1 (en) 2022-03-24
EP4028020A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
CR20220110A (es) Profármacos antivirales y composiciones farmacéuticas de los mismos
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
PH12019550039A1 (en) Dihydropyrimidine compound and preparation method and use thereof
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
WO2016086177A3 (en) Compositions and methods for hiv quasi-species excision from hiv-1-infected patients
EP3757105A3 (en) Polycyclic pyridone derivative having integrase inhibitory activity
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
PH12015501156A1 (en) Pharmaceutical compositions
EA201900025A1 (ru) Противовирусное иммунотропное средство для лечения орви
MX2018013662A (es) Sistema de entrega de farmacos para la entrega de agentes antivirales.
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
EP3526236A4 (en) SIGNATURE-BASED HUMAN IMMUNODEFICIENCY VIRUS VACCINES (ENV) CONTAINING SIGNS AND METHODS OF USE THEREOF
PT3917930T (pt) Inibidores da replicação do vírus da imunodeficiência humana
EP4066839A4 (en) PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED IN THAT IT COMPRISES A COMBINATION OF AN INTEGRASE INHIBITOR AND AN ANTI-HIV AGENT
MX2022006940A (es) Composiciones farmaceuticas.
CL2023000383A1 (es) Profármacos de análogos de nucleótidos de fosfonamida y su uso farmacéutico
CR20230315A (es) Compuestos de piridotriazina sustituidos y usos de estos
MA40496A (fr) Capsacinoïdes et leurs utilisations en tant que médicaments
MX2021006993A (es) Analogos de nucleosidos de ciclopentilo como antivirales.
MX2023008004A (es) Derivado de adenosina y composicion farmaceutica que lo comprende.
WO2016025010A8 (en) A novel broad-spectrum antiviral synergistic pharmaceutical composition for the treatment and prevention of viral infections
JOP20220033A1 (ar) نظام توصيل أدوية لتوصيل العوامل المضادة للفيروسات
WO2022092995A3 (ko) Rna 인터액톰 포획 프로토콜 및 이를 활용하여 발굴한 항바이러스용 조성물
EA202191711A1 (ru) Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток
EA202091005A1 (ru) N4-гидроксицитидин и производные и связанные с этим противовирусные применения